Nanovibronix, inc. (NAOV)
Income statement / Quarterly
Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Revenues

-

101

263

79

-

54

132

77

70

65

52

52

49

61

62

57

39

40

39

29

176

25

64

-62

Cost of revenues

113

54

56

26

35

46

55

22

32

22

18

16

12

27

22

27

14

10

15

10

-

35

25

-

Cost of revenues

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-22

Gross profit

-26

47

207

53

20

8

77

55

38

43

34

36

37

34

40

30

25

30

24

19

121

-10

39

-40

Operating expenses:
Research and development

133

79

150

152

206

121

151

136

219

160

164

150

136

161

173

114

102

87

115

95

331

101

89

-90

Selling and marketing

276

228

271

321

341

345

297

229

156

109

106

94

123

120

126

145

170

73

25

109

161

142

67

-69

General and administrative

804

533

682

1,803

835

868

454

480

680

387

424

593

619

298

197

245

213

208

199

126

221

265

151

-48

Total operating expenses

1,213

840

1,103

2,276

1,382

1,334

902

845

1,054

656

694

838

878

579

496

504

485

368

339

330

690

508

307

-184

Loss from operations

-1,239

-793

-896

-2,223

-1,362

-1,326

-825

-790

-1,016

-613

-660

-802

-841

-545

-456

-474

-460

-338

-315

-311

-569

-518

-268

144

Financial income (expense), net

-

-20

-24

-32

-

-7

11

13

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of derivative liabilities

-

-

-107

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on extinguishment of derivative liability

-

-

-288

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Warrant modification expense

-

-

-

-412

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Financial expense, net (Note 12)

-

-

-

-

-

-

-

-

619

975

178

64

190

52

144

12

320

683

114

315

-

247

300

-

Financial expense, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-341

Loss before taxes

-1,230

-813

-1,101

-2,667

-1,357

-1,333

-814

-777

-1,635

-1,588

-838

-866

-1,031

-597

-600

-486

-780

-1,021

-429

-626

-780

-765

-568

-485

Income tax benefit

-37

2

6

12

-160

11

10

12

5

11

11

11

89

9

10

9

1

18

5

4

20

1

10

18

Net loss

-1,193

-815

-1,107

-2,679

-1,197

-1,344

-824

-789

-1,640

-1,599

-849

-877

-1,120

-606

-610

-495

-781

-1,039

-434

-630

-800

-766

-578

-503

Deemed dividend related to extension of February 2015 warrants to Common stock in January 2017

-

-

-

-

-

-

-

-

0

0

0

841

-

0

0

0

-

-

-

-

-

-

-

-

Total comprehensive loss attributable to holders of Common Stock

-

-

-

-

-

-

-

-

-

-1,599

-849

-1,718

-1,120

-606

-610

-495

-781

-1,039

-434

-630

-800

-766

-578

-503

Basic and diluted net loss available for holders of common stock, Series C Preferred Stock and Series D Preferred Stock

-0.15

-0.12

-0.16

-0.40

-0.18

-0.21

-0.13

-0.12

-0.27

-0.35

-0.18

-0.37

-0.25

-0.13

-0.13

-0.11

1.75

-0.23

-0.10

-2.24

-5.17

-4.94

-3.73

-3.24

Weighted average common shares outstanding: Basic and diluted

7,261

7,054

6,788

6,652

6,506

6,438

6,429

6,419

6,094

4,583

4,594

4,583

4,584

4,582

4,574

4,572

5,073

4,562

4,227

281

-

155

155

-

Weighted average number of shares of Common stock used in computing basic and diluted net loss per share

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

155